Pfizer’s GLP-1 weight management drug Xianweiying is now available for pre-order in China.
A 1.2 ml Xianweiying injection pen, with shipments starting April 27, is priced at 489 yuan (about $72).
Read Also – World’s Top Condom Maker Karex to Raise Prices Sharply as Iran War Strains Supply Chain
The treatment belongs to the GLP-1 receptor agonist class of drugs, which are also marketed locally by companies such as Novo Nordisk, Eli Lilly and Company, and Innovent Biologics, strengthening Pfizer’s position in the rapidly growing weight-loss drug market.
Sales of Novo Nordisk’s Wegovy on Alibaba’s Tmall platform and JD.com reached 260 million yuan ($38 million) in 2025, compared with 416 million yuan ($61 million) for Innovent’s Xinermei, according to a Jefferies investment bank note.
Pfizer licensed the mainland China commercialization rights for Xianweiying, also known as ecnoglutide, from Sciwind, a company based in Hangzhou, in February. The company has also recently expanded its obesity portfolio through the acquisition of Metsera and by securing another experimental GLP-1 drug from a separate developer.
